Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Hans Lennernäs Biomedical Aktiebolag
AB
Active
Org 5566040753
Rosenvägen 19, 756 52
Uppsala
Research and experimental development on natural sciences and engineering
· NACE 7210
Est. 2001
1 employees
Watchlist
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Hans Lennernäs Biomedical Aktiebolag
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2021
1M
2022
1M
2023
1M
2024
1M
2025
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2021
0M
2022
1M
2023
0M
2024
0M
2025
Income statement
SEK thousands
Item
2021
2022
2023
2024
2025
Revenue
483
780
1 264
787
999
Staff expenses
—
—
—
—
—
EBITDA
−110
484
542
−16
370
Depreciation & amort.
−0
−0
−0
−0
−0
EBIT
−110
484
542
−16
370
Net financials
20
−838
−882
−200
−95
Profit before tax
217
139
138
85
341
Tax
−53
−120
−127
−48
−87
Net profit
164
19
11
37
254
Balance sheet
SEK thousands
Item
2021
2022
2023
2024
2025
Total assets
15 273
15 144
15 047
14 554
14 480
Equity
14 497
14 332
14 156
13 997
14 047
Long-term debt
0
0
0
0
0
Short-term debt
165
271
390
256
151
Total debt
165
271
390
256
151
Financial ratios
5-year trend
EBITDA margin
37.0%
This company
15.8%
Market median
+134% vs market
2021
2025
Equity ratio
97.0%
This company
38.2%
Market median
+154% vs market
2021
2025
Return on equity
1.8%
This company
18.4%
Market median
-90% vs market
2021
2025
Net profit margin
25.4%
This company
8.1%
Market median
+214% vs market
2021
2025
Asset turnover
0.07×
This company
1.12×
Market median
-94% vs market
2021
2025
Debt / equity
0.03×
This company
0.62×
Market median
+95% vs market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
View
PDF
More on Hans Lennernäs Biomedical Aktiebolag
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
